NOTCH and phosphatidylinositide 3-kinase/phosphatase and tensin homolog deleted on chromosome ten/AKT/mammalian target of rapamycin (mTOR) signaling in T-cell development and T-cell acute lymphoblastic leukemia

References

• Artavanis-Tsakonas S, Matsuno K, Fortini ME. Notch signaling. Science 1995;268:225–232.
   PubMed Web of Science ®Google Scholar
• Ellisen LW, Bird J, West DC, et al. TAN-1, the human homolog of the Drosophila notch gene is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell 1991;66:649–661.
   PubMed Web of Science ®Google Scholar
• Weng AP, Ferrando AA, Lee W, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004;306:269–271.
   PubMed Web of Science ®Google Scholar
• Palomero T, Sulis ML, Cortina M, et al. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med 2007;13:1203–1210.
   PubMed Web of Science ®Google Scholar
• O'Neil J, Grim J, Strack P, et al. FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J Exp Med 2007;204:1813–1824.
   PubMed Web of Science ®Google Scholar
• Medyouf H, Gao X, Armstrong F, et al. Acute T-cell leukemias remain dependent on Notch signaling despite PTEN and INK4A/ARF loss. Blood 2010;115:1175–1184.
   PubMed Web of Science ®Google Scholar
• Godfrey DI, Zlotnik A. Control points in early T-cell development. Immunol Today 1993;14:547–553.
   PubMedGoogle Scholar
• Weerkamp F, de Haas EF, Naber BA, et al. Age-related changes in the cellular composition of the thymus in children. J Allergy Clin Immunol 2005;115:834–840.
   PubMed Web of Science ®Google Scholar
• Dik WA, Pike-Overzet K, Weerkamp F, et al. New insights on human T cell development by quantitative T cell receptor gene rearrangement studies and gene expression profiling. J Exp Med 2005;201: 1715–1723.
   PubMed Web of Science ®Google Scholar
• Eberl G, Littman DR. Thymic origin of intestinal alphabeta T cells revealed by fate mapping of ROR gammat+ cells. Science 2004;305:248–251.
   PubMed Web of Science ®Google Scholar
• von Boehmer H. Selection of the T-cell repertoire: receptor-controlled checkpoints in T-cell development. Adv Immunol 2004;84:201–238.
   PubMed Web of Science ®Google Scholar
• Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: cell fate control and signal integration in development. Science 1999;284:770–776.
   PubMed Web of Science ®Google Scholar
• Rebay I, Fleming RJ, Fehon RG, Cherbas L, Cherbas P, Artavanis-Tsakonas S. Specific EGF repeats of Notch mediate interactions with Delta and Serrate: implications for Notch as a multifunctional receptor. Cell 1991;67:687–699.
   PubMed Web of Science ®Google Scholar
• de Celis JF, Barrio R, del Arco A, Garcia-Bellido A. Genetic and molecular characterization of a Notch mutation in its Delta- and Serrate-binding domain in Drosophila. Proc Natl Acad Sci USA 1993;90:4037–4041.
   PubMed Web of Science ®Google Scholar
• Weinmaster G. The ins and outs of notch signalling. Mol Cell Neurosci 1997;9:91–102.
   PubMed Web of Science ®Google Scholar
• Matsuno K, Diederich RJ, Go MJ, Blaumueller CM, Artavanis-Tsakonas S. Deltex acts as a positive regulator of Notch signalling through interactions with the Notch ankyrin repeats. Development 1995;121:2633–2644.
   PubMed Web of Science ®Google Scholar
• Wu L, Aster JC, Blacklow SC, Lake R, Artavanis-Tsakonas S, Griffin JD. MAML1, a human homologue of Drosophila mastermind, is a transcriptional co-activator for NOTCH receptors. Nat Genet 2000;26:484–489.
   PubMed Web of Science ®Google Scholar
• Mumm JS, Kopan R. Notch signalling: from the outside in. Dev Biol 2000;228:151–165.
   PubMed Web of Science ®Google Scholar
• Bray SJ. Notch signalling: a simple pathway becomes complex. Nat Rev Mol Cell Biol 2006;7:678–689.
   PubMed Web of Science ®Google Scholar
• Fiuza UM, Arias AM. Cell and molecular biology of Notch. J Endocrinol 2007;194:459–474.
   PubMed Web of Science ®Google Scholar
• Jarriault S, Le Bail O, Hirsinger E, et al. Delta-1 activation of notch-1 signalling results in HES-1 transactivation. Mol Cell Biol 1998;18:7423–7431.
   PubMed Web of Science ®Google Scholar
• Kuroda K, Tani S, Tamura K, Minoguchi S, Kurooka H, Honjo T. Delta-induced Notch signalling mediated by RBP-J inhibits MyoD expression and myogenesis. J Biol Chem 1999;274:7238–7244.
   PubMed Web of Science ®Google Scholar
• Jarriault S, Brou C, Logeat F, Schroeter EH, Kopan R, Israel A. Signalling downstream of activated mammalian Notch [see comments]. Nature 1995;377:355–358.
   PubMed Web of Science ®Google Scholar
• Iso T, Sartorelli V, Chung G, Shichinohe T, Kedes L, Hamamori Y. HERP, a new primary target of Notch regulated by ligand binding. Mol Cell Biol 2001;21:6071–6079.
   PubMed Web of Science ®Google Scholar
• Chang D, Valdez P, Ho T, Robey E. MHC recognition in thymic development: distinct, parallel pathways for survival and lineage commitment. J Immunol 2000;165:6710–6715.
   PubMed Web of Science ®Google Scholar
• Deftos ML, Huang E, Ojala EW, Forbush KA, Bevan MJ. Notch1 signaling promotes the maturation of CD4 and CD8 SP thymocytes. Immunity 2000;13:73–84.
   PubMed Web of Science ®Google Scholar
• Deftos ML, He YW, Ojala EW, Bevan MJ. Correlating Notch signaling with thymocyte maturation. Immunity 1998;9:777–786.
   PubMed Web of Science ®Google Scholar
• Campese AF, Garbe AI, Zhang F, Grassi F, Screpanti I, von Boehmer H. Notch1-dependent lymphomagenesis is assisted by but does not essentially require pre-TCR signaling. Blood 2006;108:305–310.
   PubMed Web of Science ®Google Scholar
• Pirot P, Grunsven LA, Marine JC, Huylebroeck D, Bellefroid EJ. Direct regulation of the Nrarp gene promoter by the Notch signaling pathway. Biochem Biophys Res Comm 2004;322:526–534.
   PubMed Web of Science ®Google Scholar
• Maillard I, Tu L, Sambandam A, et al. The requirement for Notch signaling at the b-selection checkpoint in vivo is absolute and independent of the pre-T cell receptor. J Exp Med 2006;203:2239–2245.
   PubMed Web of Science ®Google Scholar
• Amsen D, Blander JM, Lee GR, Tanigaki K, Honjo T, Flavell RA. Instruction of distinct CD4 T helper cell fates by different Notch ligands on antigen-presenting cells. Cell 2004;117:515–526.
   PubMed Web of Science ®Google Scholar
• Tanaka S, Tsukada J, Suzuki W, et al. The interleukin-4 enhancer CNS-2 is regulated by Notch signals and controls initial expression in NKT cells and memory-type CD4 T cells. Immunity 2006;24:689–701.
   PubMed Web of Science ®Google Scholar
• Minter LM, Turley DM, Das P, et al. Inhibitors of gamma-secretase block in vivo and in vitro T helper type 1 polarization by preventing Notch upregulation of Tbx21. Nat Immunol 2005;6:680–688.
   PubMed Web of Science ®Google Scholar
• Amsen D, Antov A, Jankovic D, et al. Direct regulation of Gata3 expression determines the T helper differentiation potential of Notch. Immunity 2007;27:89–99.
   PubMed Web of Science ®Google Scholar
• Fang TC, Yashiro-Ohtani Y, del Bianco C, Knoblock DM, Blacklow SC, Pear WS. Notch directly regulates Gata3 expression during T helper 2 cell differentiation. Immunity 2007;27:100–110.
   PubMed Web of Science ®Google Scholar
• Ordentlich P, Lin A, Shen CP, et al. Notch inhibition of E47 supports the existence of a novel signalling pathway. Mol Cell Biol 1998;18:2230–2239.
   PubMed Web of Science ®Google Scholar
• Kojika S, Griffin JD. Notch receptors and hematopoiesis. Exp Hematol 2001;29:1041–1052.
   PubMed Web of Science ®Google Scholar
• Washburn T, Schweighoffer E, Gridley T, et al. Notch activity influences the alphabeta versus gammadelta T cell lineage decision. Cell 1997;88:833–843.
   PubMed Web of Science ®Google Scholar
• Hasserjian RP, Aster JC, Davi F, Weinberg DS, Sklar J. Modulated expression of Notch1 during thymocyte development. Blood 1996;88:970–976.
   PubMed Web of Science ®Google Scholar
• Anderson G, Pongracz J, Parnell S, Jenkinson EJ. Notch ligand-bearing thymic epithelial cells initiate and sustain Notch signaling in thymocytes independently of T cell receptor signalling. Eur J Immunol 2001;31:3349–3354.
   PubMed Web of Science ®Google Scholar
• Pear WS, Aster JC, Scott ML, et al. Exclusive development of T cell neoplasms in mice transplanted with bone marrow expressing activated Notch alleles. J Exp Med 1996;183:2283–2291.
   PubMed Web of Science ®Google Scholar
• Göthert JR, Brake RL, Smeets M, Dührsen U, Begley CG, Izon DJ. NOTCH1 pathway activation is an early hallmark of SCL T leukemogenesis. Blood 2007;110:3753–3762.
   PubMed Web of Science ®Google Scholar
• Wang SF, Aoki M, Nakashima Y, et al. Development of Notch-dependent T-cell leukemia by deregulated Rap1 signaling. Blood 2008;111:2878–2886.
   PubMed Web of Science ®Google Scholar
• Kindler T, Cornejo MG, Scholl C, et al. K-RasG12D-induced T-cell lymphoblastic lymphoma/leukemias harbor Notch1 mutations and are sensitive to gamma-secretase inhibitors. Blood 2008;112:3373–3382.
   PubMed Web of Science ®Google Scholar
• Radtke F, Wilson A, Mancini SJ, MacDonald HR. Notch regulation of lymphocyte development and function. Nat Immunol 2004;5:247–253.
   PubMed Web of Science ®Google Scholar
• Radtke F, Wilson A, MacDonald HR. Notch signaling in hematopoiesis and lymphopoiesis: lessons from Drosophila. BioEssays 2005;27:1117–1128.
   PubMed Web of Science ®Google Scholar
• Radtke F, Wilson A, Stark G, et al. Deficient T cell fate specification in mice with an induced inactivation of Notch1. Immunity 1999;10:547–558.
   PubMed Web of Science ®Google Scholar
• Hozumi K, Negishi N, Suzuki D, et al. Delta-like 1 is necessary for the generation of marginal zone B cells but not T cells in vivo. Nat Immunol 2004;5:638–644.
   PubMed Web of Science ®Google Scholar
• Schmitt TM, Zuniga-Pflucker JC. T-cell development, doing it in a dish. Immunol Rev 2006;209:95–102.
   PubMed Web of Science ®Google Scholar
• Rampal R, Li AS, Moloney DJ, et al. Lunatic fringe, manic fringe, and radical fringe recognize similar specificity determinants in O-fucosylated epidermal growth factor-like repeats. J Biol Chem 2005;280:42454–42463.
   PubMed Web of Science ®Google Scholar
• Koch U, Yuan JS, Harper JA, Guidos CJ. Fine-tuning Notch1 activation by endocytosis and glycosylation. Semin Immunol 2003;15:99–106.
   PubMed Web of Science ®Google Scholar
• Nie L, Perry SS, Zhao Y, et al. Regulation of lymphocyte development by cell-type-specific interpretation of Notch signals. Mol Cell Biol 2008;28:2078–2090.
   PubMed Web of Science ®Google Scholar
• Wolfer A, Wilson A, Nemir M, MacDonald HR, Radtke F. Inactivation of Notch1 impairs VDJbeta rearrangement and allows pre-TCR-independent survival of early alpha beta lineage thymocytes. Immunity 2002;16:869–879.
   PubMed Web of Science ®Google Scholar
• Ciofani M, Schmitt TM, Ciofani A, et al. Obligatory role for cooperative signaling by pre-TCR and Notch during thymocyte differentiation. J Immunol 2004;172:5230–5239.
   PubMed Web of Science ®Google Scholar
• Ge C, Stanley P. The O-fucose glycan in the ligand-binding domain of Notch1 regulates embryogenesis and T cell development. Proc Natl Acad Sci USA 2008;105:1539–1544.
   PubMed Web of Science ®Google Scholar
• Onoyama I, Tsunematsu R, Matsumoto A, et al. Conditional inactivation of Fbxw7 impairs cell-cycle exit during T cell differentiation and results in lymphomatogenesis. J Exp Med 2007;204:2875–2888.
   PubMed Web of Science ®Google Scholar
• Kitamoto T, Takahashi K, Takimoto H, et al. Functional redundancy of the Notch gene family during mouse embryogenesis: analysis of Notch gene expression in Notch3-deficient mice. Biochem Biophys Res Comm 2005;331:1154–1162.
   PubMed Web of Science ®Google Scholar
• Vercauteren SM, Sutherland HJ. Constitutively active Notch4 promotes early human hematopoietic progenitor cell maintenance while inhibiting differentiation and causes lymphoid abnormalities in vivo. Blood 2004;104:2315–2322.
   PubMed Web of Science ®Google Scholar
• Wolfer A, Bakker T, Wilson A, et al. Inactivation of Notch 1 in immature thymocytes does not perturb CD4 or CD8 T cell development. Nature 2001;2:235–241.
   Web of Science ®Google Scholar
• Plas DR, Thompson CB. Akt-dependent transformation: there is more to growth than just surviving. Oncogene 2005;24:7435–7442.
   PubMed Web of Science ®Google Scholar
• Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell 2007;129:1261–1274.
   PubMed Web of Science ®Google Scholar
• Toulany M, Baumann M, Rodemann HP. Stimulated PI3K-AKT signaling mediated through ligand or radiation-induced EGFR depends indirectly, but not directly, on constitutive K-Ras activity. Mol Cancer Res 2007;5:863–872.
   PubMed Web of Science ®Google Scholar
• Shelton JG, Steelman LS, Abrams SL, et al. Conditional EGFR promotes cell cycle progression and prevention of apoptosis in the absence of autocrine cytokines. Cell Cycle 2005;4:822–830.
   PubMed Web of Science ®Google Scholar
• Fruman DA. The role of class I phosphoinositide 3-kinase in T-cell function and autoimmunity. Biochem Soc Trans 2007;35:177–180.
   PubMed Web of Science ®Google Scholar
• Andrews S, Stevens LR, Hawkins PT. PI3K class IB pathway. Sci STKE 2007;2007(407):cm2.
   PubMedGoogle Scholar
• Deane JA, Trifilo MJ, Yballe CM, Choi S, Lane TE, Fruman DA. Enhanced T cell proliferation in mice lacking the p85beta subunit of phosphoinositide 3-kinase. J Immunol 2004;172:6615–6625.
   PubMed Web of Science ®Google Scholar
• Deane JA, Kharas MG, Oak JS, et al. T-cell function is partially maintained in the absence of class IA phosphoinositide 3-kinase signaling. Blood 2007;109:2894–2902.
   PubMed Web of Science ®Google Scholar
• Oak JS, Deane JA, Kharas MG, et al. Sjogren's syndrome-like disease in mice with T cells lacking class 1A phosphoinositide-3-kinase. Proc Natl Acad Sci USA 2006;103:16882–16887.
   PubMed Web of Science ®Google Scholar
• Sasaki T, Irie-Sasaki J, Jones RG, et al. Function of PI3Kgamma in thymocyte development, T cell activation, and neutrophil migration. Science 2000;287:1040–1046.
   PubMed Web of Science ®Google Scholar
• Okkenhaug K, Bilancio A, Farjot G, et al. Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice. Science 2002;297:1031–1034.
   PubMed Web of Science ®Google Scholar
• Webb LMC, Vigorito E, Wymann MP, Hirsch E, Turner M. Cutting edge: T cell development requires the combined activities of the p110gamma and p110delta catalytic isoforms of phosphatidylinositol 3-kinase. J Immunol 2005;175:2783–2787.
   PubMed Web of Science ®Google Scholar
• Swat W, Montgrain V, Doggett TA, et al. Essential role of PI3Kdelta and PI3Kgamma in thymocyte survival. Blood 2006;107:2415–2422.
   PubMed Web of Science ®Google Scholar
• Hagenbeek TJ, Naspetti M, Malergue F, et al. The loss of PTEN allows TCR alphabeta lineage thymocytes to bypass IL-7 and pre-TCR-mediated signaling. J Exp Med 2004;200:883–894.
   PubMed Web of Science ®Google Scholar
• Xue L, Chiang L, Kang C, Winoto A. The role of the PI3K-AKT kinase pathway in T-cell development beyond the beta checkpoint. Eur J Immunol 2008;38:3200–3207.
   PubMed Web of Science ®Google Scholar
• Zinda MJ, Johnson MA, Paul JD, et al. AKT-1, -2, and -3 are expressed in both normal and tumor tissues of the lung, breast, prostate, and colon. Clin Cancer Res 2001;7:2475–2479.
   PubMed Web of Science ®Google Scholar
• Juntilla MM, Wofford JA, Birnbaum MJ, Rathmell JC, Koretzky GA. Akt1 and Akt2 are required for αβ thymocyte survival and differentiation. Proc Natl Acad Sci USA 2007;104:12105–12110.
   PubMed Web of Science ®Google Scholar
• Jones RG, Parsons M, Bonnard M, et al. Protein kinase B regulates T lymphocyte survival, nuclear factor kappaB activation, and Bcl-X(L) levels in vivo. J Exp Med 2000;191:1721–1734.
   PubMedGoogle Scholar
• Ciofani M, Zuniga-Pflucker JC. Notch promotes survival of pre-T cells at the beta-selection checkpoint by regulating cellular metabolism. Nat Immunol 2005;6:881–888.
   PubMed Web of Science ®Google Scholar
• Zeiser R, Negrin RS. Interleukin-2 receptor downstream events in regulatory T cells: implications for the choice of immunosuppressive drug therapy. Cell Cycle 2008;7:458–462.
   PubMed Web of Science ®Google Scholar
• Sauer S, Bruno L, Hertweck A, et al. T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR. Proc Natl Acad Sci USA 2008;105:7797–802.
   PubMed Web of Science ®Google Scholar
• Aster JC, Xu L, Karnell FG, Patriub V, Pui JC, Pear WS. Essential roles for ankyrin repeat and transactivation domains in induction of T-cell leukemia by Notch1. Mol Cell Biol 2000;20:7505–7515.
   PubMed Web of Science ®Google Scholar
• Hinton HJ, Clarke RG, Cantrell DA. Antigen receptor regulation of phosphoinositide-dependent kinase 1 pathways during thymocyte development. FEBS Lett 2006;580:5845–5850.
   PubMed Web of Science ®Google Scholar
• Mao C, Tili EG, Dose M, et al. Unequal contribution of Akt isoforms in the double-negative to double-positive thymocyte transition. J Immunol 2007;178:5443–5453.
   PubMedGoogle Scholar
• Kelly AP, Finlay DK, Hinton HJ, et al. Notch-induced T cell development requires phosphoinositide-dependent kinase 1. EMBO J 2007;26:3441–3445.
   PubMed Web of Science ®Google Scholar
• Hinton HJ, Alessi DR, Cantrell DA. The serine kinase phosphoinositide-dependent kinase 1 (PDK1) regulates T cell development. Nat Immunol 2004;5:539–545.
   PubMed Web of Science ®Google Scholar
• Lee SY, Kumano K, Masuda S, et al. Mutations of the Notch1 gene in T-cell acute lymphoblastic leukemia: analysis in adults and children. Leukemia 2005;19:1841–1843.
   PubMed Web of Science ®Google Scholar
• Mansour MR, Linch DC, Foroni L, Goldstone AH, Gale RE. High incidence of Notch-1 mutations in adult patients with T-cell acute lymphoblastic leukemia. Leukemia 2006;20:537–539.
   PubMed Web of Science ®Google Scholar
• O'Neil J, Calvo J, McKenna K, et al. Activating Notch1 mutations in mouse models of T-ALL. Blood 2006;107:781–785.
   PubMed Web of Science ®Google Scholar
• Weng AP, Aster JC. Multiple niches for Notch in cancer: context is everything. Curr Opin Genet Dev 2004;14:48–54.
   PubMed Web of Science ®Google Scholar
• Leong KG, Karsan A. Recent insights into the role of Notch signaling in tumorigenesis. Blood 2006;107:2223–2233.
   PubMed Web of Science ®Google Scholar
• Bellavia D, Campese AF, Checquolo S, et al. Combined expression of pTalpha and Notch3 in T cell leukemia identifies the requirement of preTCR for leukemogenesis. Proc Natl Acad Sci USA 2002;99:3788–3793.
   PubMed Web of Science ®Google Scholar
• Felli MP, Vacca A, Calce A, et al. PKC theta mediates pre-TCR signaling and contributes to Notch3-induced T-cell leukemia. Oncogene 2005;24:992–1000.
   PubMed Web of Science ®Google Scholar
• Sade H, Krishna S, Sarin A. The anti-apoptotic effect of Notch-1 requires p56lck-dependent, Akt/PKB-mediated signaling in T cells. J Biol Chem 2004;279:2937–2944.
   PubMed Web of Science ®Google Scholar
• Guo D, Ye J, Dai J, et al. Notch-1 regulates Akt signaling pathway and the expression of cell cycle regulatory proteins cyclin D1, CDK2 and p21 in T-ALL cell lines. Leuk Res 2009;33:678–685.
   PubMedGoogle Scholar
• Talora C, Campese AF, Bellavia D, et al. Pre-TCR-triggered ERK signalling-dependent downregulation of E2A activity in Notch3-induced T-cell lymphoma. EMBO Rep 2003;4:1067–1072.
   PubMed Web of Science ®Google Scholar
• Mungamuri SK, Yang X, Thor AD, Somasundaram K. Survival signaling by Notch1: mammalian target of rapaMYC in (mTOR)-dependent inhibition of p53. Cancer Res 2006;66:4715–4724.
   PubMed Web of Science ®Google Scholar
• Chan SM, Weng AP, Tibshirani R, Aster JC, Utz PJ. Notch signals positively regulate activity of the mTOR pathway in T-cell acute lymphoblastic leukemia. Blood 2007;110:278–286.
   PubMed Web of Science ®Google Scholar
• Bellavia D, Campese AF, Alesse E, et al. Constitutive activation of NF-kappaB and T-cell leukemia/lymphoma in Notch3 transgenic mice. EMBO J 2000;19:3337–3348.
   PubMed Web of Science ®Google Scholar
• Palomero T, Lim WK, Odom DT, et al. NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proc Natl Acad Sci USA 2006;103:18261–18266.
   PubMed Web of Science ®Google Scholar
• Lin YW, Nichols RA, Letterio JJ, Aplan PD. Notch1 mutations are important for leukemic transformation in murine models of precursor-T leukemia/lymphoma. Blood 2006;107:2540–2543.
   PubMed Web of Science ®Google Scholar
• Zhu YM, Zhao WL, Fu JF, et al. NOTCH1 mutations in T-cell acute lymphoblastic leukemia: prognostic significance and implication in multifactorial leukemogenesis. Clin Cancer Res 2006;12:3043–3049.
   PubMed Web of Science ®Google Scholar
• Mansour MR, Duke V, Foroni L, et al. Notch-1 mutations are secondary events in some patients with T-cell acute lymphoblastic leukemia. Clin Cancer Res 2007;13:6964–6969.
   PubMed Web of Science ®Google Scholar
• Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002;296:1655–1657.
   PubMed Web of Science ®Google Scholar
• Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2002;2:489–501.
   PubMed Web of Science ®Google Scholar
• Fry MJ. Phosphoinositide 3-kinase signalling in breast cancer: how big a role might it play? Breast Cancer Res 2001;3:304–312.
   PubMed Web of Science ®Google Scholar
• Lin X, Böhle AS, Dohrmann P, et al. Overexpression of phosphatidylinositol 3-kinase in human lung cancer. Langenbecks Arch Surg 2001;386:293–301.
   PubMed Web of Science ®Google Scholar
• Krasilnikov M, Adler V, Fuchs SY, et al. Contribution of phosphatidylinositol 3-kinase to radiation resistance in human melanoma cells. Mol Carcinog 1999;24:64–69.
   PubMed Web of Science ®Google Scholar
• Martínez-Lorenzo MJ, Anel A, Monleón I, et al. Tyrosine phosphorylation of the p85 subunit of phosphatidylinositol 3-kinase correlates with high proliferation rates in sublines derived from the Jurkat leukemia. Int J Biochem Cell Biol 2000;32:435–445.
   PubMed Web of Science ®Google Scholar
• Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004;304:554.
   PubMed Web of Science ®Google Scholar
• Carpten JD, Faber AL, Horn C, et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 2007;448:39–44.
   PubMed Web of Science ®Google Scholar
• DeGraffenried LA, Fulcher L, Friedrichs WE, Grünwald V, Ray RB, Hidalgo M. Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3kinase/Akt pathway. Ann Oncol 2004;15:1510–1516.
   PubMed Web of Science ®Google Scholar
• Hay N. The Akt-mTOR tango and its relevance to cancer. Cancer Cell 2005;8:179–183.
   PubMed Web of Science ®Google Scholar
• Huang HP, Shih YW, Chang YC, Hung CN, Wang CJ. Chemoinhibitory effect of mulberry anthocyanins on melanoma metastasis involved in the Ras/PI3K pathway. J Agric Food Chem 2008;56:9286–9293.
   Web of Science ®Google Scholar
• Harir N, Boudot C, Friedbichler K, et al. Oncogenic Kit controls neoplastic mast cell growth through a Stat5/PI3-kinase signaling cascade. Blood 2008;112:2463–2473.
   PubMed Web of Science ®Google Scholar
• McCubrey JA, Steelman LS, Abrams SL, et al. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul 2006;46:249–279.
   PubMedGoogle Scholar
• Hildebrandt MA, Yang H, Hung MC, et al. Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy. J Clin Oncol 2009;27:857–871.
   PubMed Web of Science ®Google Scholar
• Opitz I, Soltermann A, Abaecherli M, et al. PTEN expression is a strong predictor of survival in mesothelioma patients. Eur J Cardiothorac Surg 2008;33:502–506.
   PubMed Web of Science ®Google Scholar
• Zhou L, Huang Y, Li J, Wang Z. The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma. Med Oncol 2010;27:255–261.
   PubMed Web of Science ®Google Scholar
• Wu Z, Gioeli D, Conaway M, Weber MJ, Theodorescu D. Restoration of PTEN expression alters the sensitivity of prostate cancer cells to EGFR inhibitors. Prostate 2008;68:935–944.
   PubMed Web of Science ®Google Scholar
• Huang WC, Hung MC. Induction of Akt activity by chemotherapy confers acquired resistance. J Formos Med Assoc 2009;108:180–194.
   PubMed Web of Science ®Google Scholar
• Chen KF, Yeh PY, Hsu C, et al. Bortezomib overcomes TRAIL resistance in hepatocellular carcinoma cells in part through the inhibition of PI3K/Akt pathway. J Biol Chem 2009;284:11121–11133.
   PubMed Web of Science ®Google Scholar
• Cullion K, Draheim KM, Hermance N, et al. Targeting the Notch1 and mTOR pathways in a mouse T-ALL model. Blood 2009;113:6172–6181.
   PubMed Web of Science ®Google Scholar
• Silva A, Yunes JA, Cardoso BA, et al. PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability. J Clin Invest 2008;118:3762–3774.
   PubMed Web of Science ®Google Scholar
• Jotta PY, Ganazza MA, Silva A, et al. Negative prognostic impact of PTEN mutation in pediatric T-cell acute lymphoblastic leukemia. Leukemia 2010;24:239–242.
   PubMed Web of Science ®Google Scholar
• Gutierrez A, Sanda T, Grebliunaite R, et al. High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. Blood 2009;114:647–650.
   PubMed Web of Science ®Google Scholar
• Remke M, Pfister S, Kox C, et al. High-resolution genomic profiling of childhood T-ALL reveals frequent copy-number alterations affecting the TGF-beta and PI3K-AKT pathways and deletions at 6q15-16.1 as a genomic marker for unfavorable early treatment response. Blood 2009;114:1053–1062.
   PubMed Web of Science ®Google Scholar
• Suzuki A, de la Pompa JL, Stambolic V, et al. High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr Biol 1998;8:1169–1178.
   PubMed Web of Science ®Google Scholar
• Podsypanina K, Ellenson LH, Nemes A, et al. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci USA 1999;96:1563–1568.
   PubMed Web of Science ®Google Scholar
• Di Cristofano A, Pesce B, Cordon-Cardo C, Pandolfi PP. Pten is essential for embryonic development and tumour suppression. Nat Genet 1998;19:348–355.
   PubMed Web of Science ®Google Scholar
• Suzuki A, Yamaguchi MT, Ohteki T, et al. T cell-specific loss of Pten leads to defects in central and peripheral tolerance. Immunity 2001;14:523–534.
   PubMed Web of Science ®Google Scholar
• Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006;7:606–619.
   PubMed Web of Science ®Google Scholar
• Trotman LC, Pandolfi PP. PTEN and p53: who will get the upper hand? Cancer Cell 2003;3:97–99.
   PubMed Web of Science ®Google Scholar
• Yilmaz OH, Valdez R, Theisen BK, et al. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 2006;441:475–482.
   PubMed Web of Science ®Google Scholar
• Sulis ML, Parsons R. PTEN: from pathology to biology. Trends Cell Biol 2003;13:478–483.
   PubMed Web of Science ®Google Scholar
• Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 1998;273:13375–13378.
   PubMed Web of Science ®Google Scholar
• Hoemann CD, Beaulieu N, Girard L, Rebai N, Jolicoeur P. Two distinct Notch1 mutant alleles are involved in the induction of T-cell leukemia in c-MYC transgenic mice. Mol Cell Biol 2000;20:3831–3842.
   PubMed Web of Science ®Google Scholar
• Feldman BJ, Hampton T, Cleary ML. A carboxy-terminal deletion mutant of Notch1 accelerates lymphoid oncogenesis in E2A-PBX1 transgenic mice. Blood 2000;96:1906–1913.
   PubMedGoogle Scholar
• Weng AP, Nam Y, Wolfe MS, et al. Growth suppression of pre-T acute lymphoblastic leukemia cells by inhibition of notch signaling. Mol Cell Biol 2003;23:655–664.
   PubMed Web of Science ®Google Scholar
• Weng AP, Millholland JM, Yashiro-Ohtani Y, et al. c-MYC is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. Genes Dev 2006;20:2096–2109.
   PubMed Web of Science ®Google Scholar
• Sharma VM, Calvo JA, Draheim KM, et al. Notch1 contributes to mouse T-cell leukemia by directly inducing the expression of c-MYC. Mol Cell Biol 2006;26:8022–8031.
   PubMed Web of Science ®Google Scholar
• Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995;378:785–789.
   PubMed Web of Science ®Google Scholar
• Espinosa L, Ingles-Esteve J, Aguilera C, Bigas A. Phosphorylation by glycogen synthase kinase-3 beta down-regulates Notch activity, a link for Notch and Wnt pathways. J Biol Chem 2003;278:32227–32235.
   PubMed Web of Science ®Google Scholar
• Foltz DR, Santiago MC, Berechid BE, Nye JS. Glycogen synthase kinase-3beta modulates notch signaling and stability. Curr Biol 2002;12:1006–1011.
   PubMed Web of Science ®Google Scholar
• Jin YH, Kim H, Oh M, Ki H, Kim K. Regulation of Notch1 NICD and Hes1 expressions by GSK-3alpha beta. Mol Cells 2009;27:15–19.
   PubMed Web of Science ®Google Scholar
• Calzavara E, Chiaramonte R, Cesana D, Basile A, Sherbet GV, Comi P. Reciprocal regulation of Notch and PI3K/Akt signalling in T-ALL cells in vitro. J Cell Biochem 2008;103:1405–1412.
   PubMed Web of Science ®Google Scholar
• Bedogni B, Warneke JA, Nickoloff BJ, Giaccia AJ, Powell MB. Notch1 is an effector of Akt and hypoxia in melanoma development. J Clin Invest 2008;118:3660–3670.
   PubMed Web of Science ®Google Scholar
• Breit S, Stanulla M, Flohr T, et al. Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia. Blood 2006;108:1151–1157.
   PubMed Web of Science ®Google Scholar
• Lones MA, Heerema NA, Le Beau MM, et al. Chromosome abnormalities in advanced stage lymphoblastic lymphoma of children and adolescents: a report from CCG-E08. Cancer Genet Cytogenet 2007;172:1–11.
   PubMed Web of Science ®Google Scholar
• van Grotel M, Meijerink JP, van Wering ER, et al. Prognostic significance of molecular-cytogenetic abnormalities in pediatric T-ALL is not explained by immunophenotypic differences. Leukemia 2008;22:124–131.
   PubMed Web of Science ®Google Scholar
• Deangelo D, Stone R, Silverman L, et al. A phase I clinical trial of the Notch inhibitor MK-0752 in patients with T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) and other leukemias. J Clin Oncol 2006;24(18 Suppl.): Abstract 6585.
   Web of Science ®Google Scholar
• Real PJ, Tosello V, Palomero T, et al. Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia. Nat Med 2009;15:50–58.
   PubMed Web of Science ®Google Scholar
• Chiarini F, Grimaldi C, Ricci F, et al. Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin in inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia. Cancer Res 2010;70:8097–8107.
   PubMed Web of Science ®Google Scholar
• Chiarini F, Falà F, Tazzari PL, et al. Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin in as a new therapeutic option for T-cell acute lymphoblastic leukemia. Cancer Res 2009;69:3520–3528.
   PubMed Web of Science ®Google Scholar
• Gu L, Zhou C, Liu H, et al. Rapamycin sensitizes T-ALL cells to dexamethasone-induced apoptosis. J Exp Clin Cancer Res 2010;29:150.
   PubMed Web of Science ®Google Scholar
• Sanda T, Li X, Gutierrez A, et al. Interconnecting molecular pathways in the pathogenesis and drug sensitivity of T-cell acute lymphoblastic leukemia. Blood 2010;115:1735–1745.
   Google Scholar
• Silva A, Jotta PY, Silveira AB, et al. Regulation of PTEN by CK2 and Notch1 in primary T-cell acute lymphoblastic leukemia: rationale for combined use of CK2- and gamma-secretase inhibitors. Haematologica 2010;95:674–678.
   PubMed Web of Science ®Google Scholar